Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | PREP | P48147 | 4/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.56 |
| ▸ | PRCP | P42785 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12953075 | 0.97 | TSHR (0.58) | TSHRL3MBTL1KDM4ELMNAPREP | |
| SCHEMBL3691433 | 0.91 | PREP (0.63) | TSHRL3MBTL1KDM4ELMNAPREP | |
| SCHEMBL3560163 | 0.87 | PREP (0.61) | TSHRL3MBTL1KDM4ELMNAPREP | |
| SCHEMBL13374867 | 0.87 | PREP (0.61) | TSHRL3MBTL1KDM4ELMNAPREP | |
| SCHEMBL13389110 | 0.87 | TSHR (0.65) | TSHRL3MBTL1KDM4ELMNAPREP | |
| SCHEMBL847403 | 0.86 | TSHR (0.64) | TSHRL3MBTL1KDM4ELMNAPREP | |
| SCHEMBL14893288 | 0.86 | TSHR (0.64) | TSHRL3MBTL1KDM4ELMNAPREP | |
| SCHEMBL5248816 | 0.84 | FKBP1A (0.53) | TSHRL3MBTL1KDM4ELMNAPREP | |
| SCHEMBL5248179 | 0.84 | KLK7 (0.56) | TSHRL3MBTL1KDM4ELMNAPREP | |
| SCHEMBL3562100 | 0.84 | TSHR (0.61) | TSHRL3MBTL1KDM4ELMNAPREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126986-B2 | Hetero-bicyclic derivatives as HCV inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2015-09-08 | — | — | US | disclosed |
| US-9126986-B2 | Hetero-bicyclic derivatives as HCV inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2015-09-08 | — | — | US | disclosed |
| US-20140357626-A1 | Hetero-Bicyclic Derivatives As HCV Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2014-12-04 | — | — | US | disclosed |
| US-20140357626-A1 | Hetero-Bicyclic Derivatives As HCV Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2014-12-04 | — | — | US | disclosed |
| US-8815849-B2 | Hetero-bicyclic derivatives as HCV inhibitors | JANSSEN R&D IRELAND (IE) | 2014-08-26 | — | — | US | disclosed |
| US-8815849-B2 | Hetero-bicyclic derivatives as HCV inhibitors | JANSSEN R&D IRELAND (IE) | 2014-08-26 | — | — | US | disclosed |
| US-20130123244-A1 | Hetero-Bicyclic Derivatives as HCV Inhibitors | JANSSEN R&D IRELAND (IL) | 2013-05-16 | — | — | US | disclosed |
| US-20130123244-A1 | Hetero-Bicyclic Derivatives as HCV Inhibitors | JANSSEN R&D IRELAND (IL) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357626-A1 | Hetero-Bicyclic Derivatives As HCV Inhibitors | HAVCR2, ZC3HAV1, SUB1 | TSHR 4586/4885L3MBTL1 4013/4885KDM4E 3631/4885 |
| US-20130123244-A1 | Hetero-Bicyclic Derivatives as HCV Inhibitors | HAVCR2, ZC3HAV1, SUB1 | TSHR 4569/4885L3MBTL1 3971/4885KDM4E 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.